Nature Communications (Nov 2019)
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
- Giada Zurlo,
- Xijuan Liu,
- Mamoru Takada,
- Cheng Fan,
- Jeremy M. Simon,
- Travis S. Ptacek,
- Javier Rodriguez,
- Alex von Kriegsheim,
- Juan Liu,
- Jason W. Locasale,
- Adam Robinson,
- Jing Zhang,
- Jessica M. Holler,
- Baek Kim,
- Marie Zikánová,
- Jörgen Bierau,
- Ling Xie,
- Xian Chen,
- Mingjie Li,
- Charles M. Perou,
- Qing Zhang
Affiliations
- Giada Zurlo
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Xijuan Liu
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Mamoru Takada
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Cheng Fan
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Jeremy M. Simon
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Travis S. Ptacek
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Javier Rodriguez
- Cancer Research UK Edinburgh Centre, IGMM, University of Edinburgh
- Alex von Kriegsheim
- Cancer Research UK Edinburgh Centre, IGMM, University of Edinburgh
- Juan Liu
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine
- Jason W. Locasale
- Department of Pharmacology and Cancer Biology, Duke University School of Medicine
- Adam Robinson
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Jing Zhang
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Jessica M. Holler
- Department of Pediatrics, School of Medicine, Emory University
- Baek Kim
- Department of Pediatrics, School of Medicine, Emory University
- Marie Zikánová
- Research Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague
- Jörgen Bierau
- Department of Clinical Genetics, Maastricht University Medical Centre
- Ling Xie
- Department of Biochemistry and Biophysics, University of North Carolina
- Xian Chen
- Department of Biochemistry and Biophysics, University of North Carolina
- Mingjie Li
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Charles M. Perou
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Qing Zhang
- Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- DOI
- https://doi.org/10.1038/s41467-019-13168-4
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 15
Abstract
The hydroxylase EgIN2 contributes to triple negative breast cancers. Here, using an enzyme-substrate trapping strategy, the authors identify ASDL as a bona fide substrate of EgIN2 promoting aggressive properties of TNBC via the activation of cMYC signaling.
